• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global and Maestro Partner to Offer Private Equity Firms Enhanced Visibility into Asset Level Performance

    Partnership offers streamlined value creation monitoring and reporting to support decision-making NEW YORK, Aug. 19, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) and Maestro, the leading Value Creation Management platform for private equity and a S&P Global Ventures portfolio company, have announced a strategic partnership to deliver enhanced portfolio monitoring capabilities for private equity firms and their portfolio companies. This partnership includes a native integration of the Maestro platform with S&P Global's iLEVEL portfolio monitoring system, enabling automated data entry and streamlined measurement of value creation initiatives.

    8/19/25 12:09:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery

    AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815310613/en/ Initially approved by the Food and Drug Admin

    8/15/25 8:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asia Pacific Petroleum Conference (APPEC) to Address Key Industry Issues Facing Global Energy Markets

    Premier energy summit set for September to focus on 'Navigating Trade, Technology and Transition" SINGAPORE, Aug. 15, 2025 /PRNewswire/ -- The 41st annual Asia Pacific Petroleum Conference (APPEC) by S&P Global – Asia's leading energy conference - will take place from September 8 to 11, 2025, at the Raffles City Convention Centre in Singapore. A cornerstone of the energy industry for the past 40 years, this premier gathering of close to 1,500 industry leaders, experts and executives across 65 countries aims to explore the evolving landscape of the oil and gas sector, discussin

    8/15/25 7:01:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

    4/10/25 8:19:38 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Citigroup initiated coverage on Moderna with a new price target

    Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

    3/13/25 8:15:14 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, S&P Global Mobility Eager William W

    4 - S&P Global Inc. (0000064040) (Issuer)

    8/19/25 4:05:15 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    New insider Eager William W claimed ownership of 6,202 shares (SEC Form 3)

    3 - S&P Global Inc. (0000064040) (Issuer)

    8/19/25 4:00:37 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, Market Intelligence Saha Saugata sold $1,122,240 worth of shares (2,000 units at $561.12), decreasing direct ownership by 39% to 3,150 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    8/12/25 4:01:41 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/18/25 11:07:43 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/15/25 10:40:25 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/12/25 10:45:07 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Kodiak Gas Services Set to Join S&P SmallCap 600

    NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Kodiak Gas Services Inc. (NYSE:KGS) will replace NV5 Global Inc. (NASD: NVEE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, August 06. Acuren Corp. (NYSE:TIC) is acquiring NV5 Global in a deal expected to be completed soon pending final conditions.  Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector August 06, 2025 S&P SmallCap 600 Addition Kodiak Gas Services KGS Energy August 06, 2025 S&P SmallCap 600 Deletion NV5 Global NVEE Industrials For more information about S&P Dow Jones Indices, please v

    8/1/25 5:54:00 PM ET
    $KGS
    $NVEE
    $SPGI
    Natural Gas Distribution
    Utilities
    Other Consumer Services
    Consumer Discretionary

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Bill Eager Appointed President of S&P Global Mobility and CEO Designate of Planned Standalone Public Company

    Edouard Tavernier to Transition to Strategic Advisor Role Through September 30, 2025Company Separately Reports Second Quarter 2025 Results; Conference Call Today at 8:30 a.m. EDTNEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Bill Eager, Chief Executive Officer of CARFAX, as President of S&P Global Mobility ("Mobility"), effective August 15, 2025, and CEO designate upon completion of the previously announced planned separation of Mobility into a standalone public company. Mr. Eager succeeds Edouard Tavernier, who will remain with the Company as a strategic advisor through September 30, 2025, to support a smooth transition.

    7/31/25 7:17:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Reports Second Quarter Results

    NEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported second quarter results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings. Supplemental Information/Conference Call/Webcast Details:  The Company's senior management will review the second quarter 2025 earnings results on a conference call scheduled for today, July 31, at 8:30 a.m. EDT. Additional information presented on the conference call, as well as the Company's Supplemental slide content may be found on the Company's Inves

    7/31/25 7:16:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    AstraZeneca results: H1 and Q2 2025

    Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

    7/29/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

    SC 13G/A - S&P Global Inc. (0000064040) (Subject)

    2/13/24 5:13:53 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/7/24 8:42:56 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care